Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626628 | 0.81 | — | — | |
| SCHEMBL29018972 | 0.76 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL8200858 | 0.75 | — | — | |
| SCHEMBL13078776 | 0.73 | — | — | |
| SCHEMBL18892824 | 0.72 | — | — | |
| SCHEMBL24591379 | 0.71 | — | — | |
| SCHEMBL14308057 | 0.71 | — | — | |
| SCHEMBL15060885 | 0.71 | — | — | |
| SCHEMBL4666457 | 0.69 | — | — | |
| SCHEMBL5334154 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210772-A1 | Cleavable Conjugates of Functionalized Platinum-Acridine and Platinum-Benzacridine Agents and Methods Thereof | WAKE FOREST UNIVERSITY | 2017-07-27 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080119419-A1 | Bifunctional heterocyclic compounds and methods of making and using same | BioVersys AG (CH) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119419-A1 | Bifunctional heterocyclic compounds and methods of making and using same | PCNA, DCX, ATIC | ALDH1A1 2559/4885TSHR 3922/4885 |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | ALDH1A1 2970/4885TSHR 762/4885 |
| US-20170210772-A1 | Cleavable Conjugates of Functionalized Platinum-Acridine and Platinum-Benzacridine Agents and Methods Thereof | CES2, CES1, BCHE | ALDH1A1 502/4885TSHR 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.